Ohr Pharmaceutical Inc. (OHRP) Coverage Initiated by Analysts at Brean Capital
Analysts at Brean Capital began coverage on shares of Ohr Pharmaceutical Inc. (NASDAQ:OHRP) in a report issued on Tuesday. The firm set a “hold” rating on the stock.
Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Ohr Pharmaceutical from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Wednesday, July 20th. Roth Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Ohr Pharmaceutical in a research note on Thursday, June 16th.
Shares of Ohr Pharmaceutical (NASDAQ:OHRP) opened at 2.80 on Tuesday. Ohr Pharmaceutical has a 12-month low of $2.44 and a 12-month high of $6.56. The company has a 50 day moving average of $2.73 and a 200-day moving average of $2.93. The firm’s market cap is $89.89 million.
Ohr Pharmaceutical (NASDAQ:OHRP) last issued its earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. Analysts predict that Ohr Pharmaceutical will post ($0.94) EPS for the current year.
A number of hedge funds have recently made changes to their positions in OHRP. BlackRock Fund Advisors raised its stake in shares of Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock valued at $206,000 after buying an additional 9,685 shares during the period. Vanguard Group Inc. raised its stake in shares of Ohr Pharmaceutical by 1.1% in the second quarter. Vanguard Group Inc. now owns 922,616 shares of the company’s stock valued at $2,528,000 after buying an additional 9,763 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Ohr Pharmaceutical during the second quarter valued at about $144,000. Bank of New York Mellon Corp raised its stake in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock valued at $164,000 after buying an additional 757 shares during the period. Finally, Opaleye Management Inc. acquired a new stake in shares of Ohr Pharmaceutical during the first quarter valued at about $1,175,000. Institutional investors own 11.32% of the company’s stock.
Receive News & Stock Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.